Equibles does not estimate personal net worth.
Get an email with a short summary when Puma Biotechnology, Inc. publishes a filing, an earnings call transcript or a press release.
Get PBYI alertsRoger Storms has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Puma Biotechnology, Inc. on November 5, 2026. Puma Biotechnology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Puma Biotechnology, Inc. includes Alan Auerbach (CEO and Board Member), Alan H. Auerbach (CEO and Board Member), Maximo Nougues (CFO) and 7 others.
“Before I move into the commercial review, just a reminder that I'll be making forward-looking statements. The sales team remains committed to expanding the appropriate use of Neuralink with a primary emphasis on patients at elevated risk of recurrence.”
“Before I move into the commercial review, just a reminder that I'll be making forward-looking statements. The sales team remains focused on increasing the use of Neuralink with a main focus on patients at higher risk of recurrence.”
“Before I move into the commercial review, just a reminder that I'll be making forward-looking statements. The sales team remains focused on increasing the use of Neuralink with a main focus on patients at higher risk of recurrence.”
“Well, before I move into the commercial review, just a reminder that I'll be making forward-looking statements. The sales team remains focused on expanding overall HCP reach and frequency with a strong emphasis on driving engagement when treatment decisions are being made.”
Source not stated
Biotechnology · Healthcare
